ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem
This article was originally published in Scrip
Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is working on a medicinal chemistry "trick" to enable it to develop drugs which inhibit Rho Kinase (ROCK) without causing the unwanted side-effects that have tended to interfere with the development of such compounds.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.